- Home
- FSHP vs ARMP Comparison
FSHP vs ARMP Comparison
Compare FSHP & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- ARMP
- Stock Information
- Founded
- FSHP 2018
- ARMP N/A
- Country
- FSHP United States
- ARMP United States
- Employees
- FSHP N/A
- ARMP N/A
- Industry
- FSHP
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSHP
- ARMP Health Care
- Exchange
- FSHP NYSE
- ARMP Nasdaq
- Market Cap
- FSHP 92.2M
- ARMP 52.1M
- IPO Year
- FSHP 2024
- ARMP N/A
- Fundamental
- Price
- FSHP $10.45
- ARMP $2.16
- Analyst Decision
- FSHP
- ARMP Strong Buy
- Analyst Count
- FSHP 0
- ARMP 1
- Target Price
- FSHP N/A
- ARMP $9.00
- AVG Volume (30 Days)
- FSHP 763.0
- ARMP 21.7K
- Earning Date
- FSHP 01-01-0001
- ARMP 08-12-2025
- Dividend Yield
- FSHP N/A
- ARMP N/A
- EPS Growth
- FSHP N/A
- ARMP N/A
- EPS
- FSHP 0.21
- ARMP N/A
- Revenue
- FSHP N/A
- ARMP $4,699,000.00
- Revenue This Year
- FSHP N/A
- ARMP $8.43
- Revenue Next Year
- FSHP N/A
- ARMP N/A
- P/E Ratio
- FSHP $49.03
- ARMP N/A
- Revenue Growth
- FSHP N/A
- ARMP 14.24
- 52 Week Low
- FSHP $9.99
- ARMP $0.90
- 52 Week High
- FSHP $10.48
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- ARMP 59.73
- Support Level
- FSHP N/A
- ARMP $1.93
- Resistance Level
- FSHP N/A
- ARMP $2.23
- Average True Range (ATR)
- FSHP 0.00
- ARMP 0.16
- MACD
- FSHP 0.00
- ARMP 0.02
- Stochastic Oscillator
- FSHP 0.00
- ARMP 83.67
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.